pt en es

Reactivos e instrumentos para inmunología, biología celular y biología molecular.

Bafilomycin A1 [88899-55-2]

Imprimir

Referencia HY-100558-1mg

embalaje : 1mg

Contact local distributor :

Teléfono : +1 850 650 7790

Marca : MedChemExpress

Solicitar más información

Contact local distributor :

Teléfono : +1 850 650 7790

Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis.

Para uso exclusivo en investigación. No vendemos a pacientes.

Bafilomycin A1 Estructura química

No. CAS : 88899-55-2

This product is a controlled substance and not for sale in your territory.

Based on 482 publication(s) in Google Scholar

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Aug;608(7922):413-420. [Abstract]; Huh7 cells and ASGR1 KO cells are treated with 20 nM Bafilomycin A1 for 2 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2022 Dec;40(12):1834-1844. [Abstract]; Treatment with 249C or the autophagy inhibitor Bafilomycin A1 (BafA1; 30 nM), but not with the autophagy inducer rapamycin, resulted in upregulation of autophagy markers SQSTM1/p62 and LC3-I/II over time.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Nat Biotechnol. 2022 Dec;40(12):1834-1844. [Abstract]; Treatment with 249C or the autophagy inhibitor Bafilomycin A1 (BafA1; 30 nM), but not with the autophagy inducer rapamycin, resulted in upregulation of autophagy markers SQSTM1/p62 and LC3-I/II over time.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2022 Sep;17(9):993-1003. [Abstract]; Immunofluorescence (IF) images of phagocytosis and elimination of SC2-P (red) in the absence or presence of CIPS in THP-1 differentiated macrophages. The lysosomal inhibitor Bafilomycin A1 (BM; 100 nM; 6 h) is added to macrophages 6 h before the end of culture.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2022 May 3;8(1):40. [Abstract]; The levels of mitochondrial proteins including TIM23, TOM20, and TOM22 decreased along with decreased O-GlcNAcylation levels, which can be inhibited by BafA1.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Mil Med Res. 2022 Feb 14;9(1):9. [Abstract]; GL261 and U251 cells are treated with 3-MA (5 mM), BafA1 (10 nM), AG-205 (10 µM), or RAPA (20 nM) for 1 h followed by IR or IR plus UTMD treatment for another 24 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 Sep;288:121743.; Bafilomycin A1 (Baf; 50 nM) treatment significantly increases the percentage of both RFP+-GFP+-LC3 puncta and LC3 puncta in PDLSCs at 12 and 24 h during osteogenic induction, while there is no significant difference in the percentage of RFP+-GFP+-LC3 puncta or LC3 puncta between the Baf-treated I-PDLSCs and cells without the Baf treatment.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 Sep;288:121743.; In response to the Bafilomycin A1 (Baf; 50 nM) treatment, increases LC3 II expression is observed in PDLSCs, and significant differences between the Baf-treated PDLSCs and cells without the Baf treatment are observed at 6 h and 12 h during osteogenic induction.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 Feb 17;6(1):67. [Abstract]; Representative images of cells with GFP or GFP-LC3 puncta, and the average number of GFP-LC3 puncta per cell in stable RFP-GFP-LC3 U87 cells treated with Justicidin A (JA) (0.13 μM), Justicidin B (JB) (0.13 μM), or Justicidin C (JC) (4 μM) in the presence or absence of Compound C (2.5 μM), SCH772984 (10 μM), LY294002 (25 μM), or Bafilomycin A1 (1 nM) for 24 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 May 4;33(5):971-987.e6. [Abstract]; Western blot detection of YAP expression in HEK293T cells transfected with siControl or siATP6V0d2, followed by treatment with 100 nM Bafilomycin A1 (BafA1) for 6 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Jan;19(1):67-78. [Abstract]; HeLa cells transfected with the ORF10-GFP plasmid and pEGFP-N1 are stimulated by poly(I:C) transfection and are then treated with MG132 (5 μM), Bafilomycin A1 (Baf A1; 5 nM), or Chloroquine (CQ; 40 μM) for 24 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2021 Jun 3;28(6):1074-1089.e7. [Abstract]; Viability determined by cell counts of P, SA, and SAR iPSC-HSPCs treated with the V-ATPase inhibitor Bafilomycin A1 (Baf A1; 10 nM; 48 hours) compared with untreated cells.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2021 Oct;10(12):e12153. [Abstract]; Confocal microscopy analysis of the MVB marker CD63 in Coro1a‐Flag or Coro1a‐K233R‐Flag overexpressing HeLa cells treated with DMSO or 20 nM Bafilomycin A1 (Baf A1) for 12 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 9;9(10):1032. [Abstract]; Western blot showing SQSTM1 and LC3 levels in LN229 cells after treatment with 200 μM NSC 697855 (NTZ) and 200 nM Bafilomycin A1 (BAF) for 48 h.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 3;9(10):1015. [Abstract]; Representative western blot images of LC3 (LC3I and LC3II) in primary PTC are isolated from WT and TRPC6^-/- mice after treatment with H₂O₂ (0.5 mM 12 h) in the presence and absence of Bafilomycin A1 (BAF) (20 nM).

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Dec 13;9(12):1195. [Abstract]; Western analysis of the effect of GIT1 overexpression in increasing the LC3-II level under basal or starvation conditions with or without Bafilomycin A1 (Baf, 10 nM) in HEK293T cells.

: Bafilomycin A1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Dec 13;9(12):1195. [Abstract]; Western analysis of the effect of GIT1 knockdown in lowering the LC3-II level under non-starvation or starvation conditions (1 h) with or without Bafilomycin A1 (Baf, 10 nM) in osteoclasts.

Descripciòn

IC₅₀ & Target

Macrolide

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	0.6 nM Compound: Baf A1	Cytoprotection activity against diphtheria toxin-induced cytotoxicity against human A549 cells assessed as effect on protein synthesis incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scint Cytoprotection activity against diphtheria toxin-induced cytotoxicity against human A549 cells assessed as effect on protein synthesis incubated for 20 hrs followed by replacement of [14c]-Leucine containing medium and measured after 4 hrs by liquid scint	[PMID: 31413797]
BGC-823	IC₅₀	6.47 μM Compound: 4	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
Caco-2	IC₅₀	5.49 μM Compound: 4	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
MDCK	CC₅₀	1.41 μM Compound: 3	Cytotoxicity against dog MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells incubated for 48 hrs by MTT assay	[PMID: 33631936]
NCI-H460	IC₅₀	12.41 μM Compound: 4	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]
SMMC-7721	IC₅₀	2.03 μM Compound: 4	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 26933756]

In Vitro

Bafilomycin A1 is treated to different types of membrane ATPases with the I₅₀ of 400 nmol/mg, 4 nmol/mg and 50 nmol/mg for the vacuolar ATPases of a fungus (N. crassa), a plant (Z. mays), and an animal (bovine abrenal medulla). The I₅₀ values refer as μmol of Bafilomycin A1 per mg of protein giving 50% inhibition of ATPase activity^[1].
Bafilomycin A1 ((-)-Bafilomycin A1) disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion^[2].
Bafilomycin A1 at a low concentration (1 nM) effectively and specifically inhibits and kills pediatric B-cell acute lymphoblastic leukemia cells. It targets both early and late stages of the autophagy pathway, mitochondria and induces caspase-independent apoptosis. Bafilomycin A1 induces the binding of Beclin 1 to Bcl-2, which further inhibits autophagy and promotes apoptotic cell death^[5].
The growth of the BEL-7402 hepatocellular carcinoma and HO-8910 ovarian cancer cell lines are retarded and the metastatic potential is inhibited by Bafilomycin A1. Transmission electron microscopy and assays of capsase-3 and -9 suggest that Bafilomycin A1 induces apoptosis^[6].
Bafilomycin A1 inhibits the growth of a variety of cultured cells dose-dependently, including golden hamster embryo and NIH-3T3 fibroblasts, whether or not they are transformed, and PC12 and HeLa cells. The IC₅₀ of Bafilomycin A1 for inhibition of cell growth ranges from 10 to 50 nM^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Chronic treatment with low-dose Bafilomycin A1 (0.1 mg/kg) slightly inhibits the tumor volume, but the final tumor volume does not differ significantly from the control. However, chronic treatment with high dose Bafilomycin A1 (1 mg/kg) inhibits the tumor growth significantly, compared with controls, after 21 days^[8].
Bafilomycin A1 (0.1 mg/kg or 1 mg/kg; i.p. daily for 3 days) extends the survival of B-cell acute lymphoblastic leukemia (B-ALL) xenograft mice with advanced disease^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

622.83

Fòrmula

C₃₅H₅₈O₉

No. CAS

88899-55-2

Appearance

Solid

Color

White to light yellow

SMILES

C[C@H]([C@](O[C@@H]1C(C)C)(C[C@@H](O)[C@@H]1C)O)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C\[C@@H](C)[C@@H](O)[C@@H](C)C2)=O)(02)[C@H](/C=C/C=C2\C)OC)C

Structure Classification

Antibiotics
Disease Research
Anticancer

Antibiotics
Macrolide Antibiotics

Initial Source

Microorganisms

Streptomyces griseus strains

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (80.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6056 mL	8.0279 mL	16.0557 mL
5 mM	0.3211 mL	1.6056 mL	3.2111 mL
10 mM	0.1606 mL	0.8028 mL	1.6056 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.01 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.01 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.95%

Select Batch:

SDS (481 KB)

COA (251 KB) HNMR (279 KB) RP-HPLC (244 KB) LCMS (95 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Bowman EJ, et al. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988;85(21):7972-7976. [Content Brief]

[2]. Mauvezin C, et al. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(8):1437-1438. [Content Brief]

[3]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015;100(3):345-356. [Content Brief]

[4]. Yoshimori T, et al. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707-17712 [Content Brief]

[5]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56. [Content Brief]

[6]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834. [Content Brief]

[7]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6. [Content Brief]

[8]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30. [Content Brief]

[9]. Cattani L, et al. Bafilomycin A1 and intracellular multiplication of Legionella pneumophila. Antimicrob Agents Chemother. 1997;41(1):212-214. [Content Brief]

[10]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56. [Content Brief]

Ensayo celular ^[2]	Cells are harvested using 0.05% trypsin and suspended in culture medium containing 10% FCS, and 200 µL suspension is added to each well of a 96-well plate. Cells are cultured for 20 h for adhesion. Bafilomycin A1 is added to the wells at the final concentrations of 200, 400 and 800 nM, in triplicate. At 24, 48 and 72 h, 20 µl WST-1 is added to the cells. Following incubation at 37°C for 4 h, the plates are read to determine the optical density (OD) at 435 nm with 675 nm reference using a spectrophotometer^[2]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[4]	Mice: Tumor-bearing mice are divided randomly into three experimental groups: a low-dose Bafilomycin A1 (0.1 mg/kg per day)-treated group (n=5), a high-dose Bafilomycin A1 (1 mg/kg per day)-treated group (n=5),and a control group (n=5). Tumor size is measured and tumor volume doubling time is calculated^[4]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Bowman EJ, et al. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988;85(21):7972-7976. [Content Brief] [2]. Mauvezin C, et al. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(8):1437-1438. [Content Brief] [3]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015;100(3):345-356. [Content Brief] [4]. Yoshimori T, et al. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707-17712 [Content Brief] [5]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56. [Content Brief] [6]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834. [Content Brief] [7]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6. [Content Brief] [8]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30. [Content Brief] [9]. Cattani L, et al. Bafilomycin A1 and intracellular multiplication of Legionella pneumophila. Antimicrob Agents Chemother. 1997;41(1):212-214. [Content Brief] [10]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56. [Content Brief]

[1]. Bowman EJ, et al. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988;85(21):7972-7976.

[2]. Mauvezin C, et al. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(8):1437-1438.

[3]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015;100(3):345-356.

[4]. Yoshimori T, et al. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707-17712

[5]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.

[6]. Lu X, et al. Bafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expression. Exp Ther Med. 2015 Nov;10(5):1829-1834.

[7]. Ohkuma S, et al. Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H(+)-ATPase. In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):862-6.

[8]. Ohta T, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998 Jul;185(3):324-30.

[9]. Cattani L, et al. Bafilomycin A1 and intracellular multiplication of Legionella pneumophila. Antimicrob Agents Chemother. 1997;41(1):212-214.

[10]. Yuan N, et al. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6056 mL	8.0279 mL	16.0557 mL	40.1394 mL
	5 mM	0.3211 mL	1.6056 mL	3.2111 mL	8.0279 mL
	10 mM	0.1606 mL	0.8028 mL	1.6056 mL	4.0139 mL
	15 mM	0.1070 mL	0.5352 mL	1.0704 mL	2.6760 mL
	20 mM	0.0803 mL	0.4014 mL	0.8028 mL	2.0070 mL
	25 mM	0.0642 mL	0.3211 mL	0.6422 mL	1.6056 mL
	30 mM	0.0535 mL	0.2676 mL	0.5352 mL	1.3380 mL
	40 mM	0.0401 mL	0.2007 mL	0.4014 mL	1.0035 mL
	50 mM	0.0321 mL	0.1606 mL	0.3211 mL	0.8028 mL
	60 mM	0.0268 mL	0.1338 mL	0.2676 mL	0.6690 mL
	80 mM	0.0201 mL	0.1003 mL	0.2007 mL	0.5017 mL

Bafilomycin A1 Related Classifications

Infection Cancer
Cancer Targeted Therapy Cancer Immunotherapy Cancer Metabolism and Metastasis

Membrane Transporter/Ion Channel Autophagy Anti-infection Apoptosis
Proton Pump Autophagy Antibiotic Bacterial Apoptosis

Bafilomycin A1 [88899-55-2]

Referencia HY-100558-1mg

Contact local distributor :

Marca : MedChemExpress

Contact local distributor :

Ver todos los productos específicos de isoformas Antibiotic:

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Bafilomycin A1 Related Classifications

Keywords:

Usted podría estar interesado también en los siguientes productos:

Bafilomycin A1 [88899-55-2]

Referencia HY-100558-1mg

Contact local distributor :

Marca : MedChemExpress

Contact local distributor :

Ver todos los productos específicos de isoformas Antibiotic:

Bafilomycin A1 Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Bafilomycin A1 Related Classifications

Keywords:

Usted podría estar interesado también en los siguientes productos: